Synvista Therapeutics Presents New Preclinical Data Demonstrating The Value Of Haptoglobin Genotype Testing In Diabetes At ACC Scientific Sessions
Synvista Therapeutics, Inc. (Amex: SYI) announces data from a study of diabetic mice with the Haptoglobin 2-2 genotype that show impairment in the clearance of the Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a modification of high-density lipoprotein (HDL) structure and defective reverse cholesterol transport.
More: continued here
Filed under: Diabetes on April 2nd, 2008